232 related articles for article (PubMed ID: 36304306)
1. Identification of Master Regulators Driving Disease Progression, Relapse, and Drug Resistance in Lung Adenocarcinoma.
Xu Q; Cha Q; Qin H; Liu B; Wu X; Shi J
Front Bioinform; 2022; 2():813960. PubMed ID: 36304306
[No Abstract] [Full Text] [Related]
2. Identification of hub driving genes and regulators of lung adenocarcinoma based on the gene Co-expression network.
Xu Z; Wu Z; Xu J; Zhang J; Yu B
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32196072
[TBL] [Abstract][Full Text] [Related]
3. An
Han Y; Wong FC; Wang D; Kahlert C
Cancer Inform; 2022; 21():11769351221100727. PubMed ID: 35645555
[TBL] [Abstract][Full Text] [Related]
4. Chromatin Separation Regulators Predict the Prognosis and Immune Microenvironment Estimation in Lung Adenocarcinoma.
Li Z; Ma Z; Xue H; Shen R; Qin K; Zhang Y; Zheng X; Zhang G
Front Genet; 2022; 13():917150. PubMed ID: 35873497
[No Abstract] [Full Text] [Related]
5. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Ma Y; Yang J; Ji T; Wen F
Front Genet; 2022; 13():990623. PubMed ID: 36246622
[TBL] [Abstract][Full Text] [Related]
6. The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in
Wang Z; Zhang L; Xu W; Li J; Liu Y; Zeng X; Zhong M; Zhu Y
J Inflamm Res; 2022; 15():649-667. PubMed ID: 35140497
[TBL] [Abstract][Full Text] [Related]
7. Targeting 14-3-3ζ Overcomes Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma via BMP2/Smad/ID1 Signaling.
Cui J; Song Y; Han X; Hu J; Chen Y; Chen X; Xu X; Xing Y; Lu H; Cai L
Front Oncol; 2020; 10():542007. PubMed ID: 33123465
[No Abstract] [Full Text] [Related]
8. A novel epithelial-mesenchymal transition (EMT)-related gene signature of predictive value for the survival outcomes in lung adenocarcinoma.
Cui Y; Wang X; Zhang L; Liu W; Ning J; Gu R; Cui Y; Cai L; Xing Y
Front Oncol; 2022; 12():974614. PubMed ID: 36185284
[TBL] [Abstract][Full Text] [Related]
9. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
Front Immunol; 2022; 13():783495. PubMed ID: 35222371
[TBL] [Abstract][Full Text] [Related]
11. Systematical identifications of prognostic meaningful lung adenocarcinoma subtypes and the underlying mutational and expressional characters.
Lv Z; Lei T
BMC Cancer; 2020 Jan; 20(1):56. PubMed ID: 31987030
[TBL] [Abstract][Full Text] [Related]
12. Identification of upstream regulators for prognostic expression signature genes in colorectal cancer.
Bae T; Rho K; Choi JW; Horimoto K; Kim W; Kim S
BMC Syst Biol; 2013 Sep; 7():86. PubMed ID: 24006872
[TBL] [Abstract][Full Text] [Related]
13. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
14. An integrated analysis of prognostic and immune infiltrates for hub genes as potential survival indicators in patients with lung adenocarcinoma.
Xu Z; Wang S; Ren Z; Gao X; Xu L; Zhang S; Ren B
World J Surg Oncol; 2022 Mar; 20(1):99. PubMed ID: 35354488
[TBL] [Abstract][Full Text] [Related]
15. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Wang J; Zhan X
Front Immunol; 2021; 12():752643. PubMed ID: 34887858
[TBL] [Abstract][Full Text] [Related]
16. HIF-1ɑ-regulated miR-1275 maintains stem cell-like phenotypes and promotes the progression of LUAD by simultaneously activating Wnt/β-catenin and Notch signaling.
Jiang N; Zou C; Zhu Y; Luo Y; Chen L; Lei Y; Tang K; Sun Y; Zhang W; Li S; He Q; Zhou J; Chen Y; Luo J; Jiang W; Ke Z
Theranostics; 2020; 10(6):2553-2570. PubMed ID: 32194819
[No Abstract] [Full Text] [Related]
17. Robust prognostic gene expression signatures in bladder cancer and lung adenocarcinoma depend on cell cycle related genes.
Dancik GM; Theodorescu D
PLoS One; 2014; 9(1):e85249. PubMed ID: 24465512
[TBL] [Abstract][Full Text] [Related]
18. Immune-Stromal Score Signature: Novel Prognostic Tool of the Tumor Microenvironment in Lung Adenocarcinoma.
Qi X; Qi C; Qin B; Kang X; Hu Y; Han W
Front Oncol; 2020; 10():541330. PubMed ID: 33072571
[No Abstract] [Full Text] [Related]
19. Construction and validation of a novel prognostic signature of microRNAs in lung adenocarcinoma.
Li W; Liu S; Su S; Chen Y; Sun G
PeerJ; 2021; 9():e10470. PubMed ID: 33510968
[TBL] [Abstract][Full Text] [Related]
20. TKI resistant-based prognostic immune related gene signature in LUAD, in which FSCN1 contributes to tumor progression.
Shi Y; Xu Y; Xu Z; Wang H; Zhang J; Wu Y; Tang B; Zheng S; Wang K
Cancer Lett; 2022 Apr; 532():215583. PubMed ID: 35149175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
